Prechemotherapy serum CA125 level as a predictor of survival outcome in epithelial carcinoma of the ovary.
A total of 55 patients with epithelial ovarian carcinoma treated with platinum-based chemotherapy were followed for a minimum period of 2 years. Of these 22 patients had a prechemotherapy serum CA125 level of less than 50 ku/l and 33 patients had a serum CA125 level of greater than or equal to 50 ku/l. The 5-year actuarial survival of the two groups were 75% and 10% respectively. Prechemotherapy CA125 level taken 4 weeks after debulking surgery may predict the eventual survival outcome in epithelial ovarian cancer patients who undergo chemotherapy treatment.
Davidson
N G
NG
Department of Radiotherapy, Leicester Royal Infirmary, UK.
Khanna
S
S
Kirwan
P H
PH
Bircumshaw
D
D
D015295:Antigens, Tumor-Associated, Carbohydrate / Q000097:blood*; D014408:Biomarkers, Tumor / Q000097:blood; D002277:Carcinoma / Q000097:blood / Q000188:drug therapy / Q000401:mortality*; D005260:Female; D006801:Humans; D010051:Ovarian Neoplasms / Q000097:blood / Q000188:drug therapy / Q000401:mortality*; D011379:Prognosis; D015996:Survival Rate
D015295:Antigens, Tumor-Associated, Carbohydrate; D014408:Biomarkers, Tumor